Literature DB >> 21525169

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

Andrew Parkinson1, Faraz Kazmi, David B Buckley, Phyllis Yerino, Brandy L Paris, Jeff Holsapple, Paul Toren, Steve M Otradovec, Brian W Ogilvie.   

Abstract

Metabolism-dependent inhibition (MDI) of cytochrome P450 is usually assessed in vitro by examining whether the inhibitory potency of a drug candidate increases after a 30-min incubation with human liver microsomes (HLMs). To augment the IC(50) shift, many researchers incorporate a dilution step whereby the samples, after being preincubated for 30 min with a high concentration of HLMs (with and without NADPH), are diluted before measuring P450 activity. In the present study, we show that the greater IC(50) shift associated with the dilution method is a consequence of data processing. With the dilution method, IC(50) values for direct-acting inhibitors vary with the dilution factor unless they are based on the final (postdilution) inhibitor concentration, whereas the IC(50) values for MDIs vary with the dilution factor unless they are based on the initial (predilution) concentration. When the latter data are processed on the final inhibitor concentration, as is commonly done, the IC(50) values for MDI (shifted IC(50) values) decrease by the magnitude of the dilution factor. The lower shifted IC(50) values are a consequence of data processing, not enhanced P450 inactivation. In fact, for many MDIs, increasing the concentration of HLMs actually leads to considerably less P450 inactivation because of inhibitor depletion and/or binding of the inhibitor to microsomes. A true increase in P450 inactivation and IC(50) shift can be achieved by assessing MDI by a nondilution method and by decreasing the concentration of HLMs. These results have consequences for the conduct of MDI studies and the development of cut-off criteria.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525169     DOI: 10.1124/dmd.111.038596

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.

Authors:  Matthew G McDonald; Nicholas T Au; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

2.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

3.  Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2019-05-01       Impact factor: 3.922

4.  Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.

Authors:  Jelle Reinen; Martijn Smit; Mira Wenker
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

5.  Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).

Authors:  Faraz Kazmi; Tiffini Hensley; Chad Pope; Ryan S Funk; Greg J Loewen; David B Buckley; Andrew Parkinson
Journal:  Drug Metab Dispos       Date:  2013-02-01       Impact factor: 3.922

Review 6.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

7.  Dimensionally Enhanced Antibacterial Library Screening.

Authors:  Navid J Ayon; William G Gutheil
Journal:  ACS Chem Biol       Date:  2019-11-13       Impact factor: 5.100

8.  Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.

Authors:  Edgor Cole Tolledo; Sharon Miksys; Frank J Gonzalez; Rachel F Tyndale
Journal:  Br J Pharmacol       Date:  2020-01-06       Impact factor: 8.739

9.  Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone.

Authors:  Yu Fen Zheng; Soo Hyeon Bae; Zhouchi Huang; Soon Uk Chae; Seong Jun Jo; Hyung Joon Shim; Chae Bin Lee; Doyun Kim; Hunseung Yoo; Soo Kyung Bae
Journal:  Pharmaceutics       Date:  2020-04-07       Impact factor: 6.321

10.  Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations.

Authors:  Rakshit S Tanna; Dan-Dan Tian; Nadja B Cech; Nicholas H Oberlies; Allan E Rettie; Kenneth E Thummel; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2020-10-22       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.